Zdrowie i gospodarka · 25/09/2018

FDA Releases Final Guidance on 510(k) Substantial Equivalence Determinations

The US Food and Drug Administration (FDA) has released a final guidance document outlining factors to consider when evaluating the benefit-risk profile of medical devices in 510(k) premarket notifications, particularly when devices have different technological characteristics.